Qiang Zhang
The TAME-AD trial will be a randomized, double-blind, placebo-controlled Phase IIa clinical trial to evaluate the metabolic target engagement of terazosin for the treatment of Alzheimer's disease.
This will be a single center, randomized, double-blind, placebo-controlled, Phase IIa study to assess the target engagement of terazosin (TZ) at up to 5 milligrams (MG) daily for patients with Alzheimer's disease. The primary goal of this study is to assess the target engagement of TZ in patients with DLB. This is a pilot study and is not powered to assess efficacy of this medication. Our hope is that this study will guide future studies of this medication for the disease modification of Alzheimer's disease. This study is also aimed to learn more about how patients with Alzheimer's disease pro…
INCLUSION CRITERIA: 1. Male or female, aged 50-80 years (inclusive) at the time of consent. 2. Diagnosis of Alzheimer's disease meeting the 2011 NIA-AA clinical criteria for mild cognitive impairment due to Alzheimer's disease or probable Alzheimer's disease dementia, with the clinical syndrome attributable to AD as the primary etiology in the judgment of the site investigator. 3. Alzheimer's disease pathology confirmed by an eligible biomarker: Amyloid PET scan, Cerebrospinal Fluid (CSF) Alzheimer's disease panel or blood Alzheimer's disease panel. 4. If receiving an acetylcholinesterase inh…
In this double blind, randomized, placebo controlled phase IIa clinical trial, subjects randomized into the Terazosin group will receive Terazosin hydrochloride treatment for 78 weeks. Participants will start at 1mg daily for the first 2 weeks, then the dosage will be increased to 5mg daily over 6 weeks, and continued through the end of the study.
In this double blind, randomized, placebo controlled phase IIa clinical trial, subjects randomized into the placebo group will receive placebo for 78 weeks.
Arctuva estimate
Verify or correct the compensation shown for this listing.